Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) and family company Napo reported new data at ESPGHAN 2026 on oral liquid crofelemer as adjunctive therapy for pediatric intestinal failure (IF) due to MVID and SBS.
According to Jaguar, long-term treatment showed up to 48% and 40% PS reductions and no significant abnormalities, with a planned NDA filing for MVID in mid‑2027.
Jaguar Health (NASDAQ:JAGX) will convert all Series O Convertible Preferred Stock, issued as a recent one-time stock dividend, into Common Stock at a rate of 3.209 shares per preferred share at 12:00 pm ET on June 25, 2026.
Cash will be paid for fractional shares based on a $2.68 price. Jaguar highlights its crofelemer program for rare intestinal failure diseases, including MVID and SBS-IF, recent proof-of-concept data with up to 37% parenteral support reduction, and an NDA filing targeted for the first half of 2027.
Jaguar Health (NASDAQ:JAGX) has completed submission of a New Animal Drug Application to the FDA Center for Veterinary Medicine seeking full approval of crofelemer (Canalevia-CA1) for treating chemotherapy-induced diarrhea (CID) in dogs.
The pivotal effectiveness study showed statistically significant results: after 3 days of twice-daily treatment, dogs had average stool considered normal. In owner surveys, 77% believed Canalevia-CA1 was effective, and about 40% reported complete CID resolution versus 10.5% without CID treatment.
Jaguar Health (NASDAQ:JAGX) announced that its board is exploring a range of strategic alternatives, including mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. This review is aligned with the anticipated completion of clinical work to support a targeted NDA filing for its crofelemer-based prescription drug candidate for rare intestinal failure diseases.
In an ongoing investigator-initiated proof-of-concept trial in pediatric patients with intestinal failure due to MVID and SBS-IF, crofelemer has shown up to a 37% reduction in parenteral support. A third-party report estimates the nutritional support market for MVID at about $1.1 billion in 2026, rising to approximately $1.5 billion in 2033.
Jaguar Health (NASDAQ:JAGX) announced positive preclinical results from Magdalena Biosciences, its joint venture with Filament Health, for a whole-leaf coca extract drug candidate aimed at post-GLP-1 weight loss management.
In a 20-day mouse study on a high-fat diet, the extract prevented weight gain without reducing food intake or increasing activity.
Jaguar Health (NASDAQ:JAGX)/b) announced that founder, president and CEO Lisa Conte will present virtually at the on Wednesday, June 24, 2026 at 1:00 PM Eastern. Investors can register online, and a replay of the webcast will be available after the conference.
Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all five proposals at the May 22, 2026 Annual Meeting, which was adjourned to June 8, 2026.
Founder, president & CEO Lisa Conte will present virtually at the Emerging Growth Conference on June 10, 2026.
Jaguar Health (NASDAQ:JAGX) highlighted how ethnobotanical research and sustainable harvesting of the Croton lechleri tree underpin development of crofelemer, an FDA-approved oral botanical drug for noninfectious diarrhea in adults with HIV/AIDS.
Crofelemer liquid and powder formulations are in development as adjunctive therapies for rare intestinal failure disorders MVID and SBS-IF, supported by a pivotal trial with extension phase, ESPGHAN 2026 presentations, proof-of-concept PS reductions up to 37% in MVID and 15% in SBS-IF, and complex CMC that may hinder generic replication.
Jaguar Health (NASDAQ:JAGX) reported that Nasdaq notified the company on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and its securities remain listed and traded.
Q1 2026 net revenue increased 816% year-over-year and 527% sequentially, supported by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1. Jaguar is focusing on its pivotal-stage crofelemer program for rare intestinal failure, targeting an NDA in mid-2027 and seeking a development and commercialization partner.
Jaguar Health (NASDAQ:JAGX) reported strong Q1 2026 revenue growth driven by U.S. licensing of Mytesi and Canalevia-CA1 to Future Pak. Total net revenue rose 816% year over year to $20.3 million, with license and grant revenue of $19.1 million.
Income from operations reached $10.2 million versus a prior-year loss, while net loss to common shareholders narrowed to $7.0 million. Non-GAAP recurring EBITDA loss improved to $5.1 million. Jaguar is prioritizing crofelemer development for rare-disease intestinal failure indications.